Abiopharma

CADRENAL THERAPEUTICS, INC. (CVKD) Announces Clinical Trial Update CADRENAL THERAPEUTICS, INC. (CVKD) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: diabetes, inflammation
• Diseases/Conditions: non-obese diabetic mice
• Update Type: Trial Timeline Adjustment
• Primary Factors: Patient Enrollment, Regulatory Process
• Collaboration: INC
  • targeting inflammatory consequences of obesity and Type 2 diabetes; 12-LOX inhibition improving glucose homeostasis and peripheral inflammation in the setting of obesity and type 2 diabetes; 12-LOX inhibition having potential applications across multiple areas; Cadrenal’s 12-LOX inhibitor blocking inflammatory signals in adipose tissues and the pancreas – key drivers of the metabolic derangements that accompany adiposity and diabetes; CAD-1005
  • expected including support for CAD-1005
  • targeting 12-LOX specifically, a pathway crucial to the primary immune mechanisms that cause HIT, and addressing the root cause of HIT; CAD-1005